# Panitumumab (ABX-EGF) Monotherapy in Patients With Metastatic Colorectal Cancer

> **NCT00089635** · PHASE2 · COMPLETED · sponsor: **Amgen** · enrollment: 203 (actual)

## Conditions studied

- Colorectal Cancer
- Metastases

## Interventions

- **DRUG:** Panitumumab

## Key facts

- **NCT ID:** NCT00089635
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-08-01
- **Primary completion:** 2007-01-01
- **Final completion:** 2008-08-01
- **Target enrollment:** 203 (ACTUAL)
- **Last updated:** 2022-11-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00089635

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00089635, "Panitumumab (ABX-EGF) Monotherapy in Patients With Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00089635. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*